Human multiple myeloma cells are sensitized to topoisomerase II inhibitors by CRM1 inhibition.
Topoisomerase IIalpha (topo IIalpha) is exported from the nucleus of human myeloma cells by a CRM1-dependent mechanism at cellular densities similar to those found in patient bone marrow. When topo IIalpha is trafficked to the cytoplasm, it is not in contact with the DNA; thus, topo IIalpha inhibitors are unable to induce DNA-cleavable complexes and cell death. Using a CRM1 inhibitor or a CRM1-specific small interfering RNA (siRNA), we were able to block nuclear export of topo IIalpha as shown by immunofluorescence microscopy. Human myeloma cell lines and patient myeloma cells isolated from bone marrow were treated with a CRM1 inhibitor or CRM1-specific siRNA and exposed to doxorubicin or etoposide at high cell densities. CRM1-treated cell lines or myeloma patient cells were 4-fold more sensitive to topo II poisons as determined by an activated caspase assay. Normal cells were not significantly affected by CRM1-topo II inhibitor combination treatment. Cell death was correlated with increased DNA double-strand breaks as shown by the comet assay. Band depletion assays of CRM1 inhibitor-exposed myeloma cells showed increased topo IIalpha covalently bound to DNA. Topo IIalpha knockdown by a topo IIalpha-specific siRNA abrogated the CRM1-topo II therapy synergistic effect. These results suggest that blocking topo IIalpha nuclear export sensitizes myeloma cells to topo II inhibitors. This method of sensitizing myeloma cells suggests a new therapeutic approach to multiple myeloma.
Turner
Joel G
JG
Experimental Therapeutics Program and Department of Blood and Marrow Transplantation, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, USA.
Marchion
Douglas C
DC
Dawson
Jana L
JL
Emmons
Michael F
MF
Hazlehurst
Lori A
LA
Washausen
Peter
P
Sullivan
Daniel M
DM
D000903:Antibiotics, Antineoplastic / Q000494:pharmacology; D000951:Antigens, Neoplasm / Q000378:metabolism; D019046:Bone Marrow Neoplasms / Q000188:drug therapy* / Q000201:enzymology / Q000473:pathology; D002452:Cell Count; D016923:Cell Death / Q000187:drug effects; D045744:Cell Line, Tumor; D004250:DNA Topoisomerases, Type II / Q000378:metabolism; D004273:DNA, Neoplasm / Q000378:metabolism; D004268:DNA-Binding Proteins / Q000037:antagonists & inhibitors* / Q000378:metabolism; D004317:Doxorubicin / Q000494:pharmacology; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D006801:Humans; D028884:Karyopherins / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000378:metabolism; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000201:enzymology / Q000473:pathology; D011485:Protein Binding; D021381:Protein Transport / Q000187:drug effects; D011753:Pyrones / Q000494:pharmacology; D034741:RNA, Small Interfering; D018160:Receptors, Cytoplasmic and Nuclear / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000378:metabolism; D059005:Topoisomerase II Inhibitors; D000097606:Exportin 1 Protein
D000903:Antibiotics, Antineoplastic; D000951:Antigens, Neoplasm; D004250:DNA Topoisomerases, Type II; D004273:DNA, Neoplasm; D004268:DNA-Binding Proteins; D004317:Doxorubicin; D004791:Enzyme Inhibitors; D028884:Karyopherins; D011753:Pyrones; D034741:RNA, Small Interfering; D018160:Receptors, Cytoplasmic and Nuclear; D059005:Topoisomerase II Inhibitors; D000097606:Exportin 1 Protein; C429103:ratjadone
Mol Pharmacol. 2000 Oct;58(4):677-83
10999936
Cancer Treat Res. 1991;57:57-99
1686723
Cancer Res. 2006 Feb 15;66(4):2338-45
16489039
Br J Haematol. 2003 Oct;123(1):34-44
14510940
Mol Cell Biol. 2004 May;24(10):4395-406
15121858
Br J Cancer. 1996 Aug;74(4):648-9
8761384
Cancer Res. 2000 Oct 15;60(20):5747-53
11059769
Exp Cell Res. 2003 Jan 15;282(2):59-69
12531692
Exp Cell Res. 2003 Jun 10;286(2):321-31
12749860
Appl Microbiol Biotechnol. 2003 Aug;62(2-3):174-9
12679852
Exp Cell Res. 2004 May 1;295(2):421-31
15093741
Biochemistry. 1989 Jun 27;28(13):5680-7
2550059
Proc Natl Acad Sci U S A. 2003 Mar 18;100(6):3239-44
12629207
Mol Cell Biol. 2000 Dec;20(23):8969-82
11073996
Pharm Res. 2007 Jan;24(1):17-27
16969692
Curr Med Chem. 2008;15(26):2648-55
18991627
Cancer Res. 2009 Jan 15;69(2):510-7
19147564
Semin Hematol. 1997 Oct;34(4 Suppl 5):48-62
9408961
J Cell Sci. 2004 Jun 15;117(Pt 14):3061-71
15173319
J Antibiot (Tokyo). 1983 Jun;36(6):646-50
6874586
Blood. 2001 Sep 15;98(6):1897-903
11535527
Blood. 2005 Jul 15;106(2):698-705
15802532
Chembiochem. 2001 Sep 3;2(9):709-14
11828509
Blood. 2006 Jun 1;107(11):4514-23
16455950
FEBS Lett. 2004 Oct 8;576(1-2):27-30
15474004
Br J Haematol. 2000 Feb;108(2):331-45
10691864
EMBO J. 2002 Jan 15;21(1-2):31-42
11782423
Cell. 1993 Jul 2;73(7):1251-4
7686820
Trends Pharmacol Sci. 2000 Aug;21(8):304-8
10918636
Cancer Res. 2004 Aug 1;64(15):5225-31
15289327
Oncogene. 2003 Oct 20;22(47):7296-304
14576839
Int J Radiat Biol. 1995 Jun;67(6):655-60
7608628